Revolutionizing Rare Disease Treatment: Soligenix's Breakthroughs

8 months ago
Soligenix biopharmaceutical rare disease treatments Specialized BioTherapeutics HyBryte™ for CTCL Phase 3 study HyBryte™ marketing approval synthetic hypericin (SGX302) for psoriasis oral beclomethasone 17 21-dipropionate (BDP) for GI disorders dusquetide (SGX942) for inflammatory diseases

Soligenix: Pioneering biopharma with a game-changing therapy, HyBryte™, for cutaneous T-cell lymphoma. Positive Phase 3 results in JAMA Dermatology, tapping into a $250 million global market, and poised for $2 billion in annual sales. Explore more at https://www.redchip.com/stocks/SNGX/.

Loading comments...